In this issue, we are asking for your reactions in five areas: embryonic stem cell research, vaccine research, NIH graduate partnerships, CC patient use of alternative products, and human research protections.
Send your responses on these topics or your comments on other intramural
research concerns to us via e-mail:
<catalyst@nih.gov>;
fax:402-4303; or mail: Building 2, Room 2W23.
Bench-to-Bedside: Griff Rodgers
1. How will availability of human embryonic stem cells influence your scientific work? What exciting science do you think will emerge from the study of human embryonic stem cells?
2. Should the Vaccine Research Center continue its focus on HIV vaccines or, given recent events, accelerate the timetable for broadening its approach?
3. The NIH Graduate Partnerships Program is growing. What effect do you think this will have on NIH?
4. Do you feel comfortable with the Clinical CenterŐs new strategy to handle the use of herbs and other alternative agents by patients on protocol?
5. What is your opinion of the NIH human research protection program? What do you think of the idea of formal accreditation of such programs?
|
PUBLISHER EDITORS Lance
Liotta
|
SCIENTIFIC EDITOR MANAGING EDITOR COPY EDITOR
|
EDITORIAL ADVISORY BOARD Jorge
Carrasquillo, CC
|